Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Portfolio Pulse from Vandana Singh
Roche Holdings inadvertently disclosed the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq for non-small cell lung cancer. The update boosted shares of Iteos Therapeutics and Arcus Biosciences, who are also working on TIGIT-blocking cancer treatments. Other companies working in this area include Gilead Sciences, Merck & Co, and BeiGene.
August 23, 2023 | 7:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeiGene is also working on TIGIT-blocking cancer treatments.
BeiGene is also working on TIGIT-blocking cancer treatments, and the positive data from Roche's study could potentially boost the company's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Gilead Sciences is also working on TIGIT-blocking cancer treatments.
Gilead Sciences is also working on TIGIT-blocking cancer treatments, and the positive data from Roche's study could potentially boost the company's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Iteos Therapeutics' shares were boosted by Roche's data update.
Iteos Therapeutics is also working on TIGIT-blocking cancer treatments, and the positive data from Roche's study could potentially boost the company's stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Merck & Co is also working on TIGIT-blocking cancer treatments.
Merck & Co is also working on TIGIT-blocking cancer treatments, and the positive data from Roche's study could potentially boost the company's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Arcus Biosciences' shares were boosted by Roche's data update.
Arcus Biosciences is also working on TIGIT-blocking cancer treatments, and the positive data from Roche's study could potentially boost the company's stock.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Roche's inadvertent data disclosure has validated the TIGIT approach to cancer treatment.
The positive data from Roche's study validates the TIGIT approach to cancer treatment, which could potentially boost the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100